Bibliographie
1. Kunkel, T. A. Celebrating DNA’s Repair Crew. Cell 163, 1301–3 (2015).
2. Abegglen, L. M. et al. Potential Mechanisms for Cancer Resistance in Elephants and Comparative Cellular Response to DNA Damage in Humans. JAMA 314, 1850–60 (2015).
3. Krug, N. et al. Allergen-induced asthmatic responses modified by a GATA3- specific DNAzyme. N. Engl. J. Med. 372, 1987–95 (2015).
4. Bel, E. H. et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N. Engl. J. Med. 371, 1189–97 (2014).
5. Brusselle, G. G., Bracke, K. & Lahousse, L. Targeted therapy with inhaled corticosteroids in COPD according to blood eosinophil counts. Lancet. Respir.
Med. 3, 416–7 (2015).
6. Martinez, F. J. et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet (London, England) 385, 857–66 (2015).
7. Brahmer, J. et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N. Engl. J. Med. 373, 123–35 (2015).
8. Jänne, P. A. et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med. 372, 1689–99 (2015).
9. Cowie, M. R. et al. Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure. N. Engl. J. Med. 373, 1095–105 (2015).
10. Couzin-Frankel, J. Cancer Immunotherapy. Science (80-. ). 342, 1432–1433 (2013).
11. Ansell, S. M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N. Engl. J. Med. 372, 311–9 (2015).
12. Burger, J. A. et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N. Engl. J. Med. 373, 2425–37 (2015).
13. Chanan-Khan, A. et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet. Oncol. (2015).
doi:10.1016/S1470-2045(15)00465-9
14. Muehlenbachs, A. et al. Malignant Transformation of Hymenolepis nana in a Human Host. N. Engl. J. Med. 373, 1845–52 (2015).
15. Cannon, C. P. et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N. Engl. J. Med. 372, 2387–97 (2015).
16. Robinson, J. G. et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372, 1489–99 (2015).
17. Clark, N. P. et al. Bleeding, Recurrent Venous Thromboembolism, and Mortality Risks During Warfarin Interruption for Invasive Procedures. JAMA Intern. Med. 175, 1163–8 (2015).
18. Douketis, J. D. et al. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N. Engl. J. Med. 373, 823–33 (2015).
19. Feldman, T. et al. Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation. J. Am. Coll. Cardiol. 66, 2844–2854 (2015).
20. Maisano, F. et al. Cardioband, a transcatheter surgical-like direct mitral valve annuloplasty system: early results of the feasibility trial. Eur. Heart J. (2015).
doi:10.1093/eurheartj/ehv603
21. Reynolds, D. et al. A Leadless Intracardiac Transcatheter Pacing System. N.
Engl. J. Med. 374, 533–41 (2016).
22. Kapadia, S. R. et al. 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet (London, England) 385,
2485–91 (2015).
23. Thyregod, H. G. H. et al. Transcatheter Versus Surgical Aortic Valve
Replacement in Patients With Severe Aortic Valve Stenosis: 1-Year Results From the All-Comers NOTION Randomized Clinical Trial. J. Am. Coll. Cardiol. 65, 2184–94 (2015).
24. Langley, R. G. et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. N. Engl. J. Med. 371, 326–38 (2014).
25. Thaçi, D. et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J. Am. Acad. Dermatol. 73, 400–9 (2015).
26. Mease, P. J. et al. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N. Engl. J. Med. 373, 1329–39 (2015).
27. McInnes, I. B. et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double- blind, placebo-controlled, phase 3 trial. Lancet (London, England) 386, 1137–
46 (2015).
28. Kavanaugh, A. et al. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. J. Rheumatol.
42, 479–88 (2015).
29. Bannister, C. A. et al. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes, Obes. Metab. 16, 1165–1173 (2014).
30. Vlotides, G. & Mertens, P. R. Sodium-glucose cotransport inhibitors:
mechanisms, metabolic effects and implications for the treatment of diabetic patients with chronic kidney disease. Nephrol. Dial. Transplant 30, 1272–6 (2015).
31. Zinman, B. et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N. Engl. J. Med. 373, 2117–28 (2015).
32. von Hurst, P. R., Stonehouse, W. & Coad, J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient – a randomised, placebo-controlled trial. Br.
J. Nutr. 103, 549–555 (2010).
33. Talaei, A., Mohamadi, M. & Adgi, Z. The effect of vitamin D on insulin resistance in patients with type 2 diabetes. Diabetol. Metab. Syndr. 5, 1–5 (2013).
34. Zhu, Y. et al. High uric acid directly inhibits insulin signalling and induces insulin resistance. Biochem. Biophys. Res. Commun. 447, 707–714 (2014).
35. Williams, B. et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY- 2): a randomised, double-blind, crossover trial. Lancet (London, England) 386, 2059–68 (2015).
36. Kümpers, P. [NaCl 0.9 % for volume substitution : blessing or curse?]. Internist (Berl). 56, 773–8 (2015).
37. Rauen, T. et al. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. N. Engl. J. Med. 373, 2225–36 (2015).
